提高患者的声音:了解晚期前列腺癌患者的治疗偏好。

IF 3.4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Elizabeth R Kessler, Elizabeth Wulff-Burchfield, Jennifer Phillips, Wesley Peters, Tracy McGowan, Pankaj Aggarwal
{"title":"提高患者的声音:了解晚期前列腺癌患者的治疗偏好。","authors":"Elizabeth R Kessler, Elizabeth Wulff-Burchfield, Jennifer Phillips, Wesley Peters, Tracy McGowan, Pankaj Aggarwal","doi":"10.1007/s12325-025-03214-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>With multiple oral medications currently available for patients with prostate cancer, there is a need to understand how patients' preferences and experiences are impacted by several factors including pill burden and dosing frequency. This study aimed to understand medication preferences from patients with advanced prostate cancer (APC).</p><p><strong>Methods: </strong>We conducted a cross-sectional, online survey of patients with APC living in the USA.</p><p><strong>Results: </strong>The survey was completed by 100 patients with a median age of 65 years (range 35-79). Most patients were White (53%) with 31% Black and 15% Hispanic. Nearly half (48%) reported taking more than five pills per day and 50% reported taking more than three prescription medications per day. Nearly two-thirds (63%) reported difficulty remembering to take pills multiple times per day and 91% said they would choose a one-pill-once-daily option over a multi-pill regimen. Twenty-two (22%) patients had difficulty swallowing pills or were unsure. Of these 22, 21 (95%) considered it important that a pill can be dispersed in water or applesauce. Most patients (81%) had undergone chemotherapy previously and 80% reported taking oral medications for prostate cancer. Eighty-nine (89%) patients said they would prefer an oral treatment option compared to intravenous chemotherapy.</p><p><strong>Conclusion: </strong>Most patients prefer a one-pill-once-daily regimen. Most patients prefer the option of an oral treatment regimen over intravenous chemotherapy. When discussing treatment options, providers should consider the individual patient's preferences and engage in shared decision-making.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer.\",\"authors\":\"Elizabeth R Kessler, Elizabeth Wulff-Burchfield, Jennifer Phillips, Wesley Peters, Tracy McGowan, Pankaj Aggarwal\",\"doi\":\"10.1007/s12325-025-03214-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>With multiple oral medications currently available for patients with prostate cancer, there is a need to understand how patients' preferences and experiences are impacted by several factors including pill burden and dosing frequency. This study aimed to understand medication preferences from patients with advanced prostate cancer (APC).</p><p><strong>Methods: </strong>We conducted a cross-sectional, online survey of patients with APC living in the USA.</p><p><strong>Results: </strong>The survey was completed by 100 patients with a median age of 65 years (range 35-79). Most patients were White (53%) with 31% Black and 15% Hispanic. Nearly half (48%) reported taking more than five pills per day and 50% reported taking more than three prescription medications per day. Nearly two-thirds (63%) reported difficulty remembering to take pills multiple times per day and 91% said they would choose a one-pill-once-daily option over a multi-pill regimen. Twenty-two (22%) patients had difficulty swallowing pills or were unsure. Of these 22, 21 (95%) considered it important that a pill can be dispersed in water or applesauce. Most patients (81%) had undergone chemotherapy previously and 80% reported taking oral medications for prostate cancer. Eighty-nine (89%) patients said they would prefer an oral treatment option compared to intravenous chemotherapy.</p><p><strong>Conclusion: </strong>Most patients prefer a one-pill-once-daily regimen. Most patients prefer the option of an oral treatment regimen over intravenous chemotherapy. When discussing treatment options, providers should consider the individual patient's preferences and engage in shared decision-making.</p>\",\"PeriodicalId\":7482,\"journal\":{\"name\":\"Advances in Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12325-025-03214-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03214-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

导读:目前有多种口服药物可用于前列腺癌患者,有必要了解患者的偏好和体验如何受到包括药丸负担和给药频率在内的几个因素的影响。本研究旨在了解晚期前列腺癌(APC)患者的药物偏好。方法:我们对居住在美国的APC患者进行了横断面在线调查。结果:100例患者完成调查,中位年龄65岁(35-79岁)。大多数患者为白人(53%),31%为黑人,15%为西班牙裔。近一半(48%)的人报告每天服用5片以上的药片,50%的人报告每天服用3种以上的处方药。近三分之二(63%)的人表示,很难记住每天多次服药,91%的人表示,他们会选择每天一次的单丸方案,而不是多丸方案。22名(22%)患者有吞咽困难或不确定。在这22人中,21人(95%)认为药丸可以分散在水或苹果酱中是很重要的。大多数患者(81%)以前接受过化疗,80%的患者报告服用口服前列腺癌药物。89名(89%)患者表示,与静脉化疗相比,他们更喜欢口服治疗方案。结论:大多数患者倾向于每日一次一丸方案。比起静脉化疗,大多数病人更喜欢口服治疗方案。在讨论治疗方案时,提供者应考虑患者的个人偏好并参与共同决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer.

Introduction: With multiple oral medications currently available for patients with prostate cancer, there is a need to understand how patients' preferences and experiences are impacted by several factors including pill burden and dosing frequency. This study aimed to understand medication preferences from patients with advanced prostate cancer (APC).

Methods: We conducted a cross-sectional, online survey of patients with APC living in the USA.

Results: The survey was completed by 100 patients with a median age of 65 years (range 35-79). Most patients were White (53%) with 31% Black and 15% Hispanic. Nearly half (48%) reported taking more than five pills per day and 50% reported taking more than three prescription medications per day. Nearly two-thirds (63%) reported difficulty remembering to take pills multiple times per day and 91% said they would choose a one-pill-once-daily option over a multi-pill regimen. Twenty-two (22%) patients had difficulty swallowing pills or were unsure. Of these 22, 21 (95%) considered it important that a pill can be dispersed in water or applesauce. Most patients (81%) had undergone chemotherapy previously and 80% reported taking oral medications for prostate cancer. Eighty-nine (89%) patients said they would prefer an oral treatment option compared to intravenous chemotherapy.

Conclusion: Most patients prefer a one-pill-once-daily regimen. Most patients prefer the option of an oral treatment regimen over intravenous chemotherapy. When discussing treatment options, providers should consider the individual patient's preferences and engage in shared decision-making.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Therapy
Advances in Therapy 医学-药学
CiteScore
7.20
自引率
2.60%
发文量
353
审稿时长
6-12 weeks
期刊介绍: Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信